Biovie share price today

(BIVI)

Biovie share price is $2.7 & -₹2.70 as on 12 Dec 2024, 2.30 'hrs' IST

$2.7

▲

-0.06

(-2.17%)

Market is closed - opens 8 PM, 12 Dec 2024

View live Biovie share price in Dollar and Rupees. Guide to invest in Biovie from India. Also see the sentimental analysis on Indian investors investing in Biovie. Get details on the Indian mutual funds that are investing in Biovie. Get Analyst recommendations and forecasts along with all the Biovie's financials.

Biovie share price movements

$2.67
$2.79
$2.70
1.11%
Downside
Day's Volatility :4.3%
Upside
3.23%
$1.04
$33.10
$2.70
61.47%
Downside
52 Weeks Volatility :96.86%
Upside
91.84%

Biovie Returns

Period	Biovie Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.83%	-8.8%	0.0%
6 Months	-44.47%	-2.7%	0.0%
1 Year	-81.25%	6.5%	0.0%
3 Years	-95.1%	5.6%	-20.0%

Biovie Key Statistics

in dollars & INR

Previous Close	$2.76
Open	$2.71
Today's High	$2.79
Today's Low	$2.67
Market Capitalization	$49.0M
Today's Volume	$1.4M
52 Week High	$33.1
52 Week Low	$1.0404
Revenue TTM	$0.0
EBITDA	$-32.0M
Earnings Per Share (EPS)	$-5.08
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-208.26%

How to invest in Biovie from India?

It is very easy for Indian residents to invest directly in Biovie from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biovie stock in both rupees (INR) and dollars (USD). Search for Biovie or BIVI on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biovie or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biovie shares which would translate to -0.004 fractional shares of Biovie as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Biovie

-83%

Period: Sep 12, 2024 to Dec 11, 2024. Change in 30 Days versus previous period

Search volume for Biovie on INDmoney from India has reduced in the last 30 days as on Dec 12, 2024. -83% less investors are searching Biovie in the last 30 days versus the previous period.

Global Institutional Holdings in Biovie

Vanguard Group Inc
0.32%
Geode Capital Management, LLC
0.21%
Zullo Investment Group, Inc.
0.14%
HPM Partners LLC
0.10%
United Capital Management of KS
0.06%
Tower Research Capital LLC
0.02%

Analyst Recommendation on Biovie

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for Biovie(by analysts ranked 0 to 5 stars)

Based on 6 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biovie

What analysts predicted

Upside of 85.19%

Current:

$2.70

Target:

$5.00

Insights on Biovie

Price Movement
In the last 7 days, BIVI stock has moved down by -8.5%
BIVI vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 46.2% return, outperforming this stock by 128.7%
BIVI vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 46.4% return, outperforming this stock by 141.3%

Biovie Technicals Summary

Sell

Neutral

Buy

Biovie is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biovie Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biovie Inc	-19.4%	-44.47%	-81.25%	-95.1%	-97.3%
Regeneron Pharmaceuticals, Inc.	-5.85%	-24.7%	-11.77%	17.09%	105.58%
Biontech Se	12.25%	24.31%	22.8%	-57.11%	240.97%
Alnylam Pharmaceuticals, Inc.	-5.5%	58.79%	40.79%	36.33%	111.58%
Vertex Pharmaceuticals Incorporated	-4.43%	-2.24%	15.61%	124.98%	113.34%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biovie Inc	NA	NA	NA	-11.8	-2.08	-0.67	NA	2.51
Regeneron Pharmaceuticals, Inc.	19.27	19.27	1.17	45.03	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.24	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biovie Inc	Sell	$49.0M	-97.3%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$86.6B	105.58%	19.27	33.61%
Biontech Se	Buy	$28.0B	240.97%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$33.0B	111.58%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$122.1B	113.34%	32.84	-4.51%

About Biovie

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo

Organization	Biovie
Employees	14
CEO	Mr. Cuong Viet Do M.B.A.
Industry	Biotechnology

Management People of Biovie

Name	Title
Mr. Cuong Viet Do M.B.A.	President, CEO & Director
Ms. Joanne Wendy Kim CPA	CFO, Treasurer & Corporate Secretary
Dr. Joseph M. Palumbo M.D.	Executive VP of R&D and Chief Medical Officer
Mr. Clarence N. Ahlem	Senior Vice President of Operations
Dr. Penelope Markham Ph.D.	Senior Vice President of Liver Disease Program
Ms. Denise Smith	Senior Vice President of Manufacturing & Development
Dr. Christopher L. Reading Ph.D.	Senior Vice President of Alzheimer's Disease Program

Important FAQs about investing in Biovie from India :

What is Biovie share price today?

Biovie (BIVI) share price today is $2.70.

Can Indians buy Biovie shares?

Yes, Indians can invest in the Biovie (BIVI) from India.

With INDmoney, you can buy Biovie at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biovie at zero transaction cost.

How can I buy Biovie shares from India?

It is very easy to buy Biovie from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biovie be purchased?

Yes, you can buy fractional shares of Biovie with INDmoney app.

What are the documents required to start investing in Biovie stocks?

To start investing in Biovie, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.